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Summary
Objectives: Inadequate cellular response of chondrocytes to stress frequently terminates in osteoarthritis (OA). Adequate response is funda-
mentally modulated by concerted cytokine signaling events, directing degradation and synthesis of cartilage on articular surfaces where and
whenever necessary. Transforming growth factor (TGF)b is a prominent mediator in cartilage anabolism, although particular catabolic activ-
ities are occasionally reported. Clearly, before the TGFb signal gets through to the gene regulatory machinery, cross talk with modulators
occurs.
Method: We tested the hypothesis whether chondroitinsulfate (CS) modulates cell signaling. TGFb and/or soluble CS was added to human
articular chondrocytes (HACs) and activation of p38 and extracellular signal related kinase (ERK)1/2 was determined by immunoblot analysis.
Expression levels of mRNA of matrix metalloproteinase (MMP)-2, -3 and -13 were determined by real-time polymerase chain reaction (PCR).
Results: No signiﬁcant effects were observed unless cells were stimulated with lipopolysaccharide (LPS), invigorating catabolic metabolism in
chondrocytes. LPS effects, however, were profoundly modulated by TGFb, CS and both applied in combination. Most prominent, the silencing
of p38 stress signal by CS was superimposable to that of TGFb. Phospho-ERK1/2 levels were raised by TGFb three-fold over LPS induced
levels. In contrast, CS treatment, alone or combined with TGFb, reduced phosphorylation signiﬁcantly below LPS induced levels. Finally, sup-
pression of LPS induced MMP-13 mRNA levels resulted with CS.
Conclusion: Soluble CS modulates signaling events in chondrocytes concurrent with MMP-13 down regulation. The effects observed suggest
a feedback signaling mechanism cross talking with TGFb-signal pathways and may serve an explanation, on the cellular level, for the ben-
eﬁcial effects found in clinical studies with pharmacologic application of CS.
ª 2006 Published by Elsevier Ltd on behalf of OsteoArthritis Research Society International.
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The molecular events dominantly determining induction of
osteoarthritis (OA) initially seem to be linked to the locally
regulated capacity to build up new cartilage within the adap-
tive reconstruction of the tissue. This regulation is excep-
tionally sophisticated permitting local repair, with
degradation next to built up of cartilage on a given articular
surface. Consequently, there must be a sophisticated sig-
naling in effect which, as soon as degradation is locally ini-
tiated, serves as control for the vigor, modulates and/or
terminates degradation and eventually initiates synthesis
of new material. Typically, biological systems utilize a mech-
anism, well established as feedback control, where end
products signal to the start reactions to trim the dynamics
of the reaction chain.
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of glycan side chains produces soluble chondroitinsulfate
(CS) moieties1,2. This is a critical initial process in cartilage
turnover, as aggrecan depletion substantially accelerates
collagen digestion in cartilage3,4. We here tested the hy-
pothesis that a glycan portion of aggrecan, the CSs, as oc-
curring in initial degradation of cartilage, might fulﬁll such
a feedback control. A clinical study described that applica-
tion of soluble exogenous CS produced a protective effect
in acute cartilage degradation5, but the molecular mecha-
nisms are obscure. In addition elevation of serum levels
of CS after oral application and a pronounced tropism to-
wards the knee articular space have been reported6. It is
thinkable that the pharmacological elevation of CS levels
in joints assists the feedback and thereby contributes to
the protective effect.
Functionally outstanding among the cytokines that trans-
duce anabolic signals into human articular chondrocytes
(HACs) is transforming growth factor (TGF)b. It enhances
but also silences anabolic and catabolic gene expressions.
The main route of TGFb signaling takes place via the well
described SMAD pathway7, but emerging evidence sug-
gests intense cross talk with extracellular signal related
kinase (ERK)1/2 and p38 that brings to effect the
520 J. Holzmann et al.: Assorted effects of TGFb and chondroitinsulfate on p38 and ERK1/2 activation levelsdichotomic potency8e10. The dichotomic behavior suggests
that TGFb can crucially tip the metabolic balance to either
side by interpretation of signal cross talk. The idea is accen-
tuated by in vivo ﬁndings such as that chondrocytes upon
treatment with TGFb down regulate matrix metalloprotei-
nase (MMP) expression levels immediately adjacent to
OA lesion, whereas chondrocytes more distant from the
macroscopic lesion increase MMP mRNA11. We therefore
choose the inﬂuences of TGFb to be measured as standard
for recognized signiﬁcance.
During the experiments we learned that CS cross reacts
with TGFb induced signaling and investigated this phenom-
enon by coincubations more closely. In the consequence of
signal modulation, changes in expression levels of key
MMPs would validate the meaning of signal events pro-
duced by TGFb/CS additions. Expression and proﬁling
studies available in literature led us to select MMP-2, -3
and -1312 for determination of expression levels. In particu-
lar, MMP-3 is the most highly expressed MMP gene in nor-
mal cartilage and is signiﬁcantly reduced in OA but
nevertheless remains comparatively high, reﬂecting a cru-
cial maintenance function that becomes deregulated in
OA. A consistent ﬁnding in several reports of human OA,
as well as in animal models, is the upregulation of MMP-2
and -9 (the gelatinases) and MMP-13 (collagenase-3)13,14.
We included this selection of MMP key players in normal
cartilage degradation, in view of the facts that deregulation
is assumed to lead to OA and p38, also named stress ki-
nase, as well as ERK1/2 signaling is documented to play
a regulatory part15e18.
To simulate a catabolic situation in cell culture, we used
dedifferentiated chondrocytes in culture that were chal-
lenged by lipopolysaccharide (LPS), a bacterial cell wall
product, frequently associated as a set off for OA induc-
tion19e21. The data show that soluble CS, added to HACs
in culture, modiﬁes signal transduction signiﬁcantly in
LPS-treated cultures by particular mechanisms that modu-
late TGFb signaling. The data strongly support the pro-
posed feedback mechanism and may serve to explain at
a cellular level the beneﬁcial effect of CS described in clin-
ical studies5,22,23.
Material and methods
ISOLATION AND MONOLAYER CULTURE OF HACs
HACs were collected with informed consent and approval
of the local ethical committee as described24 from the hips
of three patients with no history of joint disease who were
scheduled to undergo joint replacement after fracture of
the femoral neck. Brieﬂy, the samples of cartilage were col-
lected in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Life
Technologies) enriched with 50 mg/ml of gentamicin and
5 mg/ml of amphotericin B (Life Technologies). The carti-
lage was diced into pieces of 1e3 mm2 and placed in
DMEM containing 200 U/ml of collagenase (Sigma Chemi-
cal, St Louis, Missouri). The tube was placed on an orbital
shaker at 25 rpm, and incubated at 37(C for 20 h. The fol-
lowing day, the digest was resuspended and centrifuged at
1000 rpm for 10 min. The pellet was gently resuspended
with calcium- and magnesium-free phosphate-buffered sa-
line (PBS). The suspension was ﬁltered through
a 100 mm mesh. Cells were centrifuged and washed, then
counted, resuspended in medium and placed into T-75-
ﬂasks at a density of 1.5 104/cm2. The growth medium
for all cultures was DMEM with 450 mg/dl of glucose (Life
Technologies). The medium was supplemented with 10%fetal bovine serum, 1% L-glutamine, 100 mg/ml of strepto-
mycin (all from PAA) and 50 mg/l of ascorbic acid (Sigma
Chemical). Cells from all preparations were pooled and pas-
saged at 80% conﬂuence by release from the dishes with
a solution of 0.1% trypsin and 0.1% ethylenediaminetetra-
acetic acid (EDTA) (PAA) in a ratio of 1:3. All the cell cul-
tures were grown in a humidiﬁed CO2 incubator (Queue
Systems Inc.) under 95% air and 5% CO2 at 37(C. For ex-
periments, cells from the eighth to the tenth passages were
seeded into 6-well plates (Greiner Bio One) at a density of
1.5 105 cells/well and grown to conﬂuence. Culture me-
dium was changed 24 h prior to incubation with 1 mg/ml
LPS (Sigma) and/or 10 ng/ml human recombinant TGFb
(Calbiochem) and/or 25 mg/ml CS for the indicated times.
All experiments were done at least in independent tripli-
cates unless separately indicated and at least duplicate de-
terminations within each experiment were used to calculate
the activities. Statistical signiﬁcance was calculated using
Graph Pad Prism’s software one column t-test and Bonfer-
roni’s Multiple Comparison Test.
ANALYSIS OF ACTIVATION OF MAP KINASE COMPONENTS
Following activation, cells were washed three times with
cold PBS and were then lysed in 70 ml lysis buffer per
well25 (10 mM Tris, pH 7.2, 150 mM NaCl, 0.5% Nonidet
P 40 and 2 mM EDTA). Protease inhibitor (Sigma P8340)
and phosphatase inhibitors (NaF, 5 mM and Na-ortho-van-
adate 0.2 mM) were added freshly prior to use. Cell lysates
were harvested with a plastic scraper, shock frozen in liquid
nitrogen and thawed and then centrifuged at 13,000 g for
15 min at 4(C. Protein concentration was determined using
a BCA protein assay (Pierce). Samples were either immedi-
ately used for Western blotting or stored at 20(C.
Sodium dodecyl sulfate (SDS) gel electrophoresis
and Western blotting
The activation status of ERK1, ERK2 and p38 was as-
sessed by Western blotting using antibodies that recognize
the activated form. Cellular extracts (at least 12 mg for
ERK1/2 and 15 mg for p38) were diluted in the ratio 1:4 in
Laemmli buffer (62.5 mM Tris, pH 6.8, 10% v/v glycerol,
1% w/v SDS, 1% v/v b-mercaptoethanol, and 0.01% w/v
bromophenol blue) and run on a 10% SDS-polyacrylamide
gel in a BIO-RAD miniprotean 3 apparatus. Proteins were
transferred onto Trans-Blot nitrocellulose (BIO-RAD) in blot-
ting buffer (50 mM Tris, 192 mM glycine, pH 8.3, containing
20% v/v methanol and 0.1% SDS) for 45 min with 400 mA
constant current. To verify blotting efﬁciency, blots were
stained in Ponceau S solution (0.1% w/v Ponceau S in
5% v/v acetic acid) for 5 min and documented by photogra-
phy. The straight relationship of this staining to ERK protein
mass was established by probing with pan-ERK antibody
signal evaluation in a series of experiments. After destain-
ing, membranes were incubated for 1 h in blocking buffer
(25 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween 20 and
5% w/v nonfat dry milk) followed by washing buffer
(25 mM Tris, pH 7.4, 150 mM NaCl, and 0.1% Tween). Sub-
sequently, membranes were incubated over night with pri-
mary antibodies (anti-pERK 1/2 and p-p38 from Cell
Signaling) 15 ml each in 15 ml of blocking buffer. After
3 10 min washing, the membranes were incubated for
60 min with a goat anti-rabbit peroxidase conjugated IgG
antibody (BIO-RAD) diluted 1:15,000 in blocking buffer.
After 3 10 min washing, antibody labeled proteins were
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Pierce 34080) and documented using ChemiImager 4400
(Biozym) with software to compute band intensities.
GENE EXPRESSION ANALYSIS
Total cellular RNA was extracted with 1 ml of Trizol re-
agent per well (Invitrogen) according to the manufacturer’s
protocol. The RNA pellet was dissolved in 20 ml diethylpyr-
ocarbonate (DEPC) (Sigma) treated water and reverse tran-
scribed using random hexamer primers (Fermentas) and
MuLV-reverse transcriptase (Fermentas). RNA extract
(10 ml) and random hexamers (2.5 mM) were incubated for
10 min at 70(C and then the master mix was added. An in-
cubation for 60 min at 37(C and ﬁnally for 5 min at 95(C
was performed to complete the reaction.
Real-time polymerase chain reaction (PCR) was carried
out using LUX (Light upon extension) Primer (Invitrogen),
Platinum Quantitative PCR SuperMix-UDG 2 (Invi-
trogen) and ROX Reference Dye (Invitrogen). LUX
Primers were designed using LUX Designer software
available in web-based format on the Invitrogen homepage
(http://www.invitrogen.com). The sequences of the primers
(see below) were checked using the NCBI Blast Software
and speciﬁcity of RT-PCR products was documented with
gel electrophoresis and resulted in a single product with
the desired length:
Real-time PCRs were carried out in 20 ml volumes in 96-
well plates (ABI PRISM 96-Well Optical Reaction Plates
and MicroAmp Optical Caps) using the ABI PRISM
7700 Sequence Detection System.
The cycling conditions were chosen according to the fol-
lowing scheme:
Quantiﬁcation was performed according to the mathemat-
ical model designed by Pfafﬂ26. Brieﬂy, for the mathematical
model it is necessary to determine the crossing points
(CPs) for each transcript. CP is deﬁned as the point at
which the ﬂuorescence rises appreciably above the back-
ground ﬂuorescence. Real-time PCR efﬁciencies were
calculated, according to E¼ 10[1/slope]. The relative
MMP-2 labeled (FAM) reverse 50- cacctg TCT CTG GGT CCA
GAT CAG GtG -30
MMP-2 unlabeled forward 50- GCA AGC CCA AGT GGG
ACA A -30
MMP-3 labeled (FAM) reverse 50- caccag GCA TCT TTT GGC
AAA TCT GGt G -30
MMP-3 unlabeled forward 50- AGC CCA GGT GTG GAG
TTC CT-30
MMP-13 labeled (FAM) reverse 50- caactt CGC AGC AAC AAG
AAA CAA G5TG-30
MMP-13 unlabeled forward 50- TGG GCC AAA TTA TGG
AGG AGAT-30
GAPDH labeled (JOE) reverse 50- caacg CCA ATA CGA CCA
AAT CCG tTG-30
GAPDH unlabeled forward 50- CCA CAT CGC TCA GAC
ACC AT-30
UDG-treatment 2 min 50(C
Initial denaturation 2 min 95(C
Denaturation 15 s 95(C
Annealing 30 s 60(C 45
Elongation 30 s 72(Cexpression ratio (R) of a target gene is calculated based
on E and the CP deviation of an unknown sample vs a con-
trol, and expressed in comparison to a reference gene.
Results
SIGNAL ACTIVATION BY TGFb AND/OR CS IN CELLS
WITHOUT LPS STIMULATION
We established the baseline values for the parameters p-
p38, and pERK1/2 under normal conditions and evaluated
thereafter the changes induced upon addition of TGFb as
the benchmark stimulus and compared CS effects to that.
To capture direct signaling effects, we measured the respec-
tive levels at 30 min and, given the possibility that signaling
occurs subsequent, with other effects invoked ahead before
the signal cascades were reached, we measured activities
in 72 h incubations in addition. The latter pictures the dura-
tion of the activation. The amount of activated, phosphory-
lated, forms of the signaling molecules was calculated
from band intensities after Western blot analysis. Antibodies
speciﬁc for the phosphorylated forms of p38 stress kinase
(p-p38) and phospho-ERK1/2 (pERK1/2) detected protein
bands at 43 kDa (p-p38) and 42 and 44 kDa (pERK1/2)
which were visualized by chemiluminescence. The inte-
grated optical densities (IODs) resulting from signal intensity
analysis of the bands are presented as relative activity (IOD
treated sample/IOD control). The results are grouped e
TGFb, CS, and TGFb and CS showing effects of short
term (grey bars) and long term (open bars) incubations in
HACs under standard conditions (Fig. 1). With TGFb addi-
tion, a tendency toward (not signiﬁcant; P> 0.05) elevated
pERK2 activation was observed (left panel Fig. 1). With
CS incubations no effects were found (middle panel). With
simultaneous coincubation of both substances, a signiﬁcant
elevation (P< 0.001) of pERK2 resulted with prolonged in-
cubation (open bar, right panel Fig. 1).
SIGNAL ACTIVATION BY LPS STIMULATION
A profound beneﬁt of CS was found preferentially in con-
ditions of ﬂorid OA and we modeled this catabolic situation
by incubation with LPS. Chondrocytes were incubated with
LPS and subjected to Western blot analysis as described
above. The IODs resulting from signal intensity analysis
are presented as relative activity (IOD LPS-treated sam-
ple/IOD control). In Fig. 2 it can be seen that the treatment
with LPS invigorated p-p38 stress kinase immediately (grey
bars) and the effect persisted for at least 72 h at the same
level (open bars). Also both pERK1 and 2 were elevated, al-
though for short duration only (grey bars). In detail, p-p38
was elevated 3.5-fold at 30 min and 72 h (P< 0.001) and
pERK1 and 2 were elevated two-fold (P< 0.05) at 30 min
only.
ACTIVATION OF MMP EXPRESSION LEVELS BY LPS
In Fig. 3 the expression levels of MMP-2, -3 and -13 were
assessed by real-time PCR and the ratios of the values re-
sulting from LPS treatment vs control treatment values are
shown. MMP-3 and -13 mRNA levels were signiﬁcantly in-
duced, while MMP-2, considered to be constitutively ex-
pressed, remained unchanged. In detail, we found that
incubation with LPS increased the expression levels of
MMP-3 more than six-fold (P< 0.01) and MMP-13 more
than nine-fold (P< 0.01) after a 24 h treatment. These
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Fig. 1. Short and long term effects of TGFb and CS on the activity levels of p38 and ERK1/2. HACs were incubated for the indicated time
periods (30 min and 72 h) with human recombinant TGFb (10 ng/ml) or CS (25 mg/ml) or both, in DMEM containing 10% FCS. Activation levels
of p38 and ERK1/2 were determined by immunoblot using phosphospeciﬁc antibodies. Equal sample loading was assessed by BCA Protein
Assay Kit and controlled by Ponceau S staining. Band intensities were calculated using the ChemiImager 4400 (Biozym). Data are presented
as relative change to control activity (IOD-treatment/IOD-control). Each bar represents the mean of three independent experiments (performed
in duplicates) SD (vertical lines). Signiﬁcant changes to control: ***¼P< 0.001 (Bonferroni’s Multiple Comparison Test).results accentuate the shift towards a catabolic state in the
HAC cultures, induced by incubation with LPS.
SIGNAL MODULATION BY TGFb AND/OR CS IN CELLS
STIMULATED WITH LPS
With the determinations of signal levels after LPS stimu-
lation in hand, we now determined the modulation of these
by addition of TGFb and CS or both in combination.
Changes induced by the indicated treatments are given
as percentage of induction (positive numbers) and reduc-
tion (negative numbers). The IOD resulting from the LPS
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Fig. 2. Activity of p38 and ERK1/2 in HACs treated with LPS.
HACs were incubated with LPS (1 mg/ml) for 30 min and 72 h
in DMEM containing 10% FCS. Activation levels of p38 and
ERK1/2 were determined by immunoblot using phosphospeciﬁc
antibodies. Equal sample loading was assessed by BCA Pro-
tein Assay Kit and controlled by Ponceau S staining. Band inten-
sities were calculated using the ChemiImager 4400. Data are
presented as relative change to control activity (IOD-treatment/
IOD-control). Each bar represents the mean of three independent
experiments (performed in duplicates) SD (vertical lines). Sig-
niﬁcant changes to control: *¼ P< 0.05, ***¼ P< 0.001 (Bonfer-
roni’s Multiple Comparison Test).challenge now serves as the basic value. Without the addi-
tion of LPS (Fig. 1) we found that TGFb as well as CS did
not change the activity of p38. But, as can be seen in Table I,
TGFb and/or CS reduced stress kinase p-p38 in LPS con-
ditioned HACs. A trend towards reduction was observed im-
mediately (30 min) and reached signiﬁcance after 72 h. In
detail, TGFb reduced p-p38 to control level (100%,
P< 0.001), that is the levels found in cells grown without
LPS, and CS additions resulted in a 54% reduction
(P< 0.01). The combined addition of both produced the
same effect (59%, P< 0.01).
With regard to ERK, the effects of the treatments were fun-
damentally different. TGFb produced an immediate statisti-
cally signiﬁcant boost of ERK1 phosphorylation (260%,
P< 0.001) that subsided after 72 h. ERK2 phosphorylation
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Fig. 3. Expression levels of MMPs 2, 3 and 13 in HACs treated with
LPS. HACs were incubated with LPS (1 mg/ml), for 24 h in DMEM
containing 10% FCS. The expression levels of MMPs and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) were determined
by RT-qPCR using the LUX Primer system. The MMP expression
levels were calculated according to the mathematical model of
Pfafﬂ (normalized to GAPDH) and presented as ratios LPS-treated
vs control. Each bar represents the mean of six independent exper-
iments (performed in triplicates)SD (vertical lines). Signiﬁcant
changes to control: **¼P< 0.01 (one-sample t-test).
523Osteoarthritis and Cartilage Vol. 14, No. 6Table I
Changes of activity levels of MAP kinases (p38 and ERK1/2) in LPS stimulated HACs treated with TGFb and/or CS
Treatment
30 min 72 h
p-p38 p-ERK 1 p-ERK 2 p-p38 p-ERK 1 p-ERK 2
TGFb 25 (14) 260 (38)*** 317 (40)*** 100 (18)*** 0 (25) 160 (25)***
CS 35 (15) 55 (18)** 73 (14)*** 54 (12)** 10 (10) 62 (15)***
TGFbþCS 38 (17) 100 (25)*** 100 (20)*** 59 (25)** 120 (15)*** 124 (25)***
LPS (1 mg/ml) stimulated HACs were incubated with human recombinant TGFb (10 ng/ml) and CS (25 mg/ml) or both combined, for the indi-
cated time points (30 min and 72 h) in DMEM containing 10% fetal calf serum (FCS). Activation levels of p38 and ERK1/2 were determined by
immunoblot using phosphospeciﬁc antibodies. Equal sample loading was assessed by BCA Protein Assay Kit and controlled by Ponceau S
staining. Data are presented as % change in activity compared to LPS treatment. Means were calculated from three independent experiments
(performed in duplicatesSD). Signiﬁcant changes to LPS treatment: **¼ P< 0.01; ***¼P< 0.001 (Bonferroni’s Multiple Comparison Test).was also stimulated immediately (317%, P< 0.001), but per-
sisted (160%, P< 0.001). In contrast, an immediate reduc-
tion of pERK1 (55%, P< 0.01) and pERK2 (73%,
P< 0.001) resulted from the addition of CS. After 72 h the re-
duction of pERK1 vanished and pERK2 was signiﬁcantly el-
evated (62%, P< 0.001). Remarkably, the combined
application of TGFb and CS produced the CS type effect:
an immediate signiﬁcant reduction of pERK1 and 2
(100%,P< 0.001). The reduction was converted into a sig-
niﬁcant stimulation after 72 h (both more than 120%,
P< 0.001). Together, the results of the experiments summa-
rized in Table I uncover a cross reference of signals pro-
duced by TGFb and CS.
RESPONSE OF LPS INDUCED MMP EXPRESSION LEVELS
TO CS TREATMENT
The disclosure of mutual and divergent signaling effects
supports the assumption that CS cross talks with TGFb ef-
fects and likely is able to modulate essential metabolic pro-
cesses, e.g., MMP expression, that are necessary for the
maintenance of cartilage integrity. We therefore tested
whether MMP expression, that was induced by LPS treat-
ment (see Fig. 3) can be inﬂuenced by incubation with
CS. In Fig. 4 the expression levels of MMP-2, -3 and -13
were assessed by real-time PCR and the ratios of the
values resulting after 24 h treatment with LPS and CS are
given as relative activity to the ones found in LPS-treated
cells. In a series of real-time PCR experiments we found
that incubation with CS signiﬁcantly decreased the expres-
sion levels of MMP-13 (30%, P< 0.05).
Discussion
Given that clinical studies show a beneﬁt when CS is
taken orally, we were interested to elucidate the molecular
details that underlie this accomplishment. CS is believed
to provide building blocks for synthesis of proteoglycans.
The evidence that the effect is more signiﬁcant in acute
stages suggests an additional process. We here examined
the hypothesis that early breakdown products of cartilage
glycosaminoglycans, set free in cartilage remodeling, cre-
ate feedback signals to the chondrocytes enabling a ﬁne
tuning of the process. We reasoned that the soluble CS
generated in the initial phase of aggrecan breakdown, is
a key candidate that can migrate to and interact with molec-
ular sensors on neighboring cells.
When incubating cells with CS we initially found no no-
ticeable effects on signal transduction. This might be dueto unresponsiveness of our cell model composed of dedif-
ferentiated chondrocytes or might be a physiological feature
of quiescent chondrocytes. We are currently investigating
the respective responses in primary differentiated HACs.
Next, we challenged the cells with LPS, a bacterial cell
wall product, described to induce a catabolic state in chon-
drocytes19e21. This treatment resulted in signiﬁcant eleva-
tion of stress signals and subsequent rise in MMP
expression. In this stage, the cells were highly responsive
to CS treatment. Stress kinases as well as MMP-13 were
reduced signiﬁcantly and thus the overall result can be
quoted as silencing of the catabolic state.
Our results also demonstrate that the impact of CS on
HAC signaling is in the magnitude of TGFb efﬁcacy.
TGFb typically modiﬁed the LPS induced catabolic
changes, but with CS and TGFb combined, the responses
were altered signiﬁcantly. We found synergism and antago-
nism of CS on TGFb effects. It will be of importance to elu-
cidate the direct molecular targets for CS on the cells, be it
membrane receptors or its involvement in cytokine trapping,
that produce the signaling effects. Besides acting as struc-
tural components of the extracellular matrix and anchoring
cells to the matrix, both extracellular and cell-surface
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Fig. 4. Expression levels of MMPs 2, 3 and 13 in HACs treated with
LPS and CS. HACs were incubated with LPS (1 mg/ml) and CS
(25 mg/ml) for 24 h in DMEM containing 10% FCS. Expression
levels of MMPs and GAPDH were determined by RT-qPCR using
the LUX Primer system (Invitrogen). The MMP expression levels
were calculated according to the mathematical model of Pfafﬂ (nor-
malized to GAPDH) and presented as relative change to LPS treat-
ment (ratios of levels of LPS and CS treated/LPS treatment). Each
bar represents the mean of six independent experiments (per-
formed in triplicates)SD (vertical lines). Signiﬁcant changes to
LPS treatment: *¼P< 0.05 (one-sample t-test).
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among them TGFb. Often, matrix-bound growth factors
are resistant to degradation by extracellular proteases and
so serve as a reservoir. During tissue growth and remodel-
ing or after infection active growth factor is released by
hydrolysis of the glycosaminoglycan chains. Moreover, the
core protein of a cell-surface proteoglycan called beta-
glycan binds TGFb and then presents it to TGFb receptors.
These examples illustrate the function of glycosaminogly-
cans as extracellular hormone reservoirs and mediators of
binding of cytokines to their cell-surface receptors. Soluble
CS might interfere with such functions and thus triggers al-
tered intracellular signaling. So far our data ﬁt to support the
hypothesis that the soluble CS, that is locally generated in
cartilage remodeling, assists in metabolic decision making
in chondrocytes and tunes the effects of TGFb. The data
are also in agreement with clinical studies that indicate
a more pronounced beneﬁcial effect of oral CS application
in severe cases of OA, presumably by antiinﬂammatory
action27.
To this end the reported experiments all support the hy-
pothesis of a regulatory feedback potency of CS that may
substantially assist the effect of substituting CS to provide
nutritional supply for synthesis of CS proteoglycans, the
main constituent of cartilage. Yet, we are far from under-
standing critical details of the mechanism.
More direct support for our assumption is currently inves-
tigated. In view of reports indicating that aggrecanase-1 is
induced by cytokines, especially TGFb28, we are interested
to examine whether a similar feedback occurs in this sys-
tem analogous to the MMP.
Numerous reports demonstrate metabolic effects of CS
on cells, that are often decidedly speciﬁc for the sulfation
position. We recently reported that soluble CSs induce
a pronounced growth modulation on length and fascicula-
tion of neurites in primary cultured neurons29. Since there
is a remarkable match in the use of certain signaling mech-
anisms in brain cells and chondrocytes we were incited to
scrutinize the possibility that a sulfation type dependent in-
teraction can as well occur in chondrocytes by CSs10,30.
We are thus currently analyzing preliminary evidence that
different sulfation patterns in CS types produce variable sig-
naling interference, with the high C6S forms being more ef-
fective in reduction of MMP-13. In view of the major risk
factor for OA, age, the concomitant signiﬁcant decrease of
the C6S/C4S ratio in synovial ﬂuid is a remarkable discov-
ery31,32. An examination of the levels of CS in synovial ﬂuid
of a collection of patients with staged OA (Kellgren and
Lawrence scale I to IV) revealed a decline of C6S/C4S ratio
from 5.6 at stage I to 2.7 at stage IV33. Such changes
would, accordingly, predict that the feedback strength will
decline with age and may thus present a new factor contrib-
uting to the elevated risk of OA with age, which could be
prevented by substituting C6S.
Anyhow, the direct molecular targets for CS that produce
the signaling effects need to be elucidated. This knowledge
will not only help to adequately streamline the application
of CS for pinpointed efﬁcacy but will uncover important
mechanisms of the regulation of cartilage growth and
maintenance.
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